Skip to main
ABBV
ABBV logo

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 53%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie has demonstrated robust financial performance, with 1Q 2025 sales reaching $13.34 billion, driven by strong sales from key immunology and oncology products, including Skyrizi, Rinvoq, Imbruvica, and Venclexta. The company has revised its FY 2025 revenue guidance upwards by $700 million to approximately $59.7 billion and increased its non-GAAP EPS guidance to a range of $12.09-$12.29, signaling ongoing confidence in its core growth drivers. Additionally, management projects global sales for the neuroscience segment to reach around $10.7 billion by 2025, reflecting positive momentum from products like Botox Therapeutic and Vraylar.

Bears say

AbbVie faces significant downside risks impacting its financial outlook, including potential disappointing commercial execution of key assets such as Skyrizi, Rinvoq, and its Aesthetics products, which could adversely affect revenue generation. The impending erosion of Humira's market share due to the entry of biosimilars, combined with limited penetration of critical offerings in the immunology and oncology segments, raises concerns about the company's ability to meet long-term growth targets. Additionally, macroeconomic challenges, particularly those affecting discretionary spending in the Aesthetics segment and pipeline development delays, further exacerbate the uncertainties surrounding AbbVie's future earnings potential.

AbbVie (ABBV) has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 53% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 15 analysts, AbbVie (ABBV) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $243.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $243.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.